Results 261 to 270 of about 11,285,853 (344)

Global research trends in pediatric bone and joint infections: A 50-year bibliometric analysis (1976-2025). [PDF]

SICOT J
Vaishya R, Johari AN, Gupta BM, Mamdapur GMN, Ali KS, Vaish A.   +5 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Predicting the Future of Aesthetic Surgery: An Artificial Intelligence Framework for Global Publication Forecasting. [PDF]

Aesthet Surg J
Karamitros G, Bouloukakis G, Giannas E, Lamaris GA, Thayer WP, Perdikis G, Lineaweaver WC, Assi P.   +7 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016-2025). [PDF]

Front Immunol
Guo B, Zhang G, Sang S, Ma X, Qi H.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Bibliometric review of worldwide scientific literature on mother-to-child transmission of HIV (1980-2023). [PDF]

Medicine (Baltimore)
Karasneh RA, Al-Azzam SI, Alzoubi KH, Zyoud SH, Sweileh WM.   +4 more
europepmc   +1 more source

An Open Pharma Vision for company-sponsored biomedical research publications. [PDF]

BMJ Open
Osório J, Baróniková S, Dews SA, Mysore S, Patrikis K, Philippon V, Rains CP, Schmidt A, Skobe C, Winchester CC.   +9 more
europepmc   +1 more source

Global research trends in the epidemiology of allergic disorders: a bibliometric and evidence-mapping review. [PDF]

Front Med (Lausanne)
Alhassan T, Almarzooqi F.
europepmc   +1 more source

Environmental Aspects in Price and Reimbursement Decisions of Medicines-A Scoping Review. [PDF]

Basic Clin Pharmacol Toxicol
Alajärvi L, Miettinen M, Timonen J.
europepmc   +1 more source